These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4927483)

  • 1. The nature of the lethal factor of Shigella flexneri.
    Jankowski S; Lachowicz TM
    Arch Immunol Ther Exp (Warsz); 1971; 19(1):47-66. PubMed ID: 4927483
    [No Abstract]   [Full Text] [Related]  

  • 2. Trials of transduction with defective Shigella flexneri phage.
    Bohdanowicz-Murek K
    Arch Immunol Ther Exp (Warsz); 1971; 19(3):327-42. PubMed ID: 4938011
    [No Abstract]   [Full Text] [Related]  

  • 3. Significance of "intracellular parasitism" in experimental Shigella cystitis.
    Tenner C; Rácz P; Serény B
    Acta Microbiol Acad Sci Hung; 1971; 18(3):179-89. PubMed ID: 4949073
    [No Abstract]   [Full Text] [Related]  

  • 4. Lysogenic conversion in the Shigella flexneri group.
    Kétyi I; Vertényi A; Financsek I
    Acta Microbiol Acad Sci Hung; 1971; 18(1):47-54. PubMed ID: 4947098
    [No Abstract]   [Full Text] [Related]  

  • 5. [Etiological factors in bacillary dysentery in Poland 1965-1979].
    Stypułkowska-Misiurewicz H; Adonajło A
    Przegl Epidemiol; 1981; 35(4):443-53. PubMed ID: 7041196
    [No Abstract]   [Full Text] [Related]  

  • 6. [Research on active immunity of man in bacillary dysentery. 3. Maintenance of the non-pathogenic character of the Shigella flexneri 2a TXXXII strain orally administered to volunteers].
    Istrati G; Meitert T; Ciufeco C
    Arch Roum Pathol Exp Microbiol; 1965 Sep; 24(3):677-86. PubMed ID: 5877879
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhanced isolation of Shigella species by extended incubation of primary isolation plates.
    Alam K; Hossain MA; Islam N; Sen SK; Sur GC; Talukder KA; Nair GB; Sack DA
    J Health Popul Nutr; 2003 Dec; 21(4):396-7. PubMed ID: 15038595
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of dysentery bacteriophage on the course of experimental cystitis produced in guinea-pigs by Shigella flexneri.
    Manolov DG; Kosturkov GB
    J Hyg Epidemiol Microbiol Immunol; 1965; 9(4):455-9. PubMed ID: 5893861
    [No Abstract]   [Full Text] [Related]  

  • 9. Bacteriological and epidemiological approach to prophylaxy for enteric infection. IV. Experimental bladder infection of Shigella.
    Anzai H; Kubota Y; Okamoto M; Sekizuka S; Nakamura T
    Kitasato Arch Exp Med; 1971 Dec; 44(3):155-66. PubMed ID: 4949632
    [No Abstract]   [Full Text] [Related]  

  • 10. Antidysentery immunoprophylaxis in the light of current data about the pathogenicity of Shigella and the antidysentery immunity.
    Meitert T
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):195-230. PubMed ID: 6443688
    [No Abstract]   [Full Text] [Related]  

  • 11. The properties of Shigella flexneri 1b strain carrying a lethal factor.
    Jankowski S; Lachowicz TM; Mulczyk M
    Acta Microbiol Pol; 1966; 15(3):213-22. PubMed ID: 4161857
    [No Abstract]   [Full Text] [Related]  

  • 12. Development and administration of live Shigella vaccines.
    Pencu E
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):231-50. PubMed ID: 6443689
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimization of virulence functions through glucosylation of Shigella LPS.
    West NP; Sansonetti P; Mounier J; Exley RM; Parsot C; Guadagnini S; Prévost MC; Prochnicka-Chalufour A; Delepierre M; Tanguy M; Tang CM
    Science; 2005 Feb; 307(5713):1313-7. PubMed ID: 15731456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antidysenteric vaccination. XIV. Immunizing action on the guinea pig conjunctiva of various toxic extracts of pathogenic Shigella flexneri 2a TI, as compared with that of live cultures of two non-pathogenic strains of Shigella flexneri 2a].
    Istrati M; Istrati G
    Arch Roum Pathol Exp Microbiol; 1966 Mar; 25(1):55-64. PubMed ID: 5973711
    [No Abstract]   [Full Text] [Related]  

  • 15. An update on Shigella vaccines.
    Ashkenazi S; Cohen D
    Isr J Med Sci; 1994; 30(5-6):495-7. PubMed ID: 8034510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine potential for inactivated shigellae.
    Osorio M; Bray MD; Walker RI
    Vaccine; 2007 Feb; 25(9):1581-92. PubMed ID: 17178431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycocalyx visualization in Shigella flexneri.
    Mora-Galindo J; Aguilar-Benavides S; González-Mendoza A; Feria-Velasco A; Jáuregui-Topete M
    Arch Invest Med (Mex); 1984; 15(3):215-22. PubMed ID: 6085609
    [No Abstract]   [Full Text] [Related]  

  • 18. On lactosepositive variants of Sh. flexneri 2a and serotype 145-46.
    Trifonova A; Tekelieva R
    Zentralbl Bakteriol Orig; 1969 Jan; 209(2):196-203. PubMed ID: 5386532
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experimental model of keratoconjunctival infections in the study of immunity against Shigella].
    Cefalù M; Puglisi C
    G Mal Infett Parassit; 1972 Apr; 24(4):281-9. PubMed ID: 5050309
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.